Medicine

The drug, avacopan, which will be available under brand name Tavneos in the next few weeks, will have a wholesale price of between $150,000 and $200,000 per patient per year.

A notion in the policy community is that competition between biologics and their biosimilars does not save patients and taxpayers as much as well-functioning generic competition.

Conceived at the start of the pandemic, COVAX had lofty goals, promising fair and equitable access to Covid-19 vaccines for every country worldwide, and giving them for free to the poorest.

The 26 research institutions have run nearly 4,600 trials testing medicines and, so far, 641 sets of results have been made available.

OTBB head Sarah Yim says FDA internal thinking is not aligned on the idea and that a lot of convincing was necessary to drop the clinical study requirement for insulin biosimilars.

When babies are born in western Kenya, where malaria is rife, many mothers are sent home from the hospital with one all-important baby gift: a bed net treated with insecticide.

Nearly a dozen state governments said they are grappling with shortages of rapid tests, which provide on-the-spot results within minutes and are crucial for COVID-19 surveillance programs.

The state of Venezuela's already overloaded and crumbling public health system, in which hospitals often lack access to even water, has pushed many to use costly private centers.

High prices and low availability still a major barrier for patients’ access to new and old medicines.

Antiviral drugs that keep some coronavirus patients out of the hospital are badly needed, and investors know it.

The suggestion was made in the latest report about treatments to be added to the WHO list of essential medicines.

Polls show that 65% of voters would oppose the legislation to lower drug prices if it reduced the supply of new drugs.

The evolving landscape for biosimilars.

For 17 of the 20 top-selling drugs in the world in 2020, pharmaceutical companies made more in revenue from U.S. sales than they did in every other country put together.

This lecture will describe the US FDA approval of aducanumab (Aduhelm) for Alzheimer disease and the implications the approval has had across the US health care system.